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Background
The CDC reports that every year more than 795,000 people in the
United States have a stroke, with 610,000 being first time strokes.
Stroke is the leading cause of serious long-term disability in the United
States. It is estimated to have a cost exceeding 46 billion dollars
annually in the United States alone.1 Over the last decade, clear
evidence has emerged to support endovascular treatment for moderate
to severe acute ischemic stroke due to large vessel occlusion.
Highly Effective Reperfusion evaluated in Multiple Endovascular
Stroke Trials (HERMES)
• Meta-analysis from six recent trials: MR CLEAN, ESCAPE,
REVASCAT, SWIFT, PRIME and EXTENDED IA trials
• Clear benefit in patients with large vessel occlusion and a National
Institute of Health Stroke Scale (NIHSS) greater than 10.
• NIHSS ≤ 10 showed a tendency toward improvement with
intervention, it failed to reach significance.2
• DEFUSE 3 trial
• Trend towards benefit in the population with a NIHSS of 6-9.3
• Guidelines from the American Heart Association (AHA) have since
expanded their class one recommendation for endovascular
treatment to include those who meet either DAWN or the broader
DEFUSE 3 criteria.
Due to the limited evidence available, endovascular treatment of
NIHSS <6 may be reasonable and currently has a IIb
recommendation from the AHA.4

Problem Statement
Can prehospital symptom improvement combined with fluid attenuated
inversion recovery (FLAIR) hypertensive vessels and multiphase
computed tomography angiography (mCTA) predict which AIS patients
with an initial segment (M1) of the middle cerebral artery (MCA)
occlusion and a NIHSS<6 are most likely to benefit from mechanical
thrombectomy?

Age (Mean in years)
Hypertension
Hyperlipidemia
Diabetes Mellitus
Coronary Artery disease
Atrial Fibrillation
Smoking in last year
Cancer
Prior Stroke
Myocardial Infarction
Mechanical Valve
CHF
OSA
Carotid disease
Similar Symptoms previously
Prior TIA
History of Migraines
Liver Disease
Renal Disease
Smoking
Alcohol
Marijuana
Statin
ACE Inhibitor
Betablocker
Aspirin
Clopidogrel
Warfarin
NOAC

Time from onset to arrival (mean in
minutes)
mRS prior to admission (mean)
NIHSS on admission (mean)
NIHSS on discharge (mean)
mRS on discharge (mean)
Length of stay (mean in days)
mRS at 90 days (mean)

•

•
•

P Value T. Test
0.193
0.467
0.192
0.241
0.063
0.094
0.872
0.429
0.147
0.007
0.333
0.506
0.083
0.007
0.044
0.024
0.322
0.322
0.836
0.770
0.318
0.001
0.358
0.289
0.033
0.775
0.083
0.591
0.159

Medical Management

Mechanical
Thrombectomy

472
0.38
2.69
1.69
2.00
3.13
2.31

P Value T.
Test
299
0.56
2.92
2.55
2.21
4.33
1.98

0.330
0.538
0.597
0.353
0.625
0.070
0.614

Mechanical
Medical Management Thrombectomy
56%
56%

0.223
0.544

0%

4%

0.159

Readmission within 90 days of stroke

25%

25%

1.000

Able to drive prior to stroke

56%

67%

0.331

Able to drive 90 days after stroke

38%

48%

0.648

Working prior to stroke

19%

44%

0.471

Working 90 days after stroke

13%

23%

0.541

Table 3. Additional comparison of medical management and MT out to 90 days.

Inclusion criteria for Predicted to Benefit (PTB) group
1 Patients with a NIHSS score greater than 2 on arrival
Patients with worsening or unchanged symptoms prior to arrival at outside
hospital and/or CSC
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Patients with an mCTA collateral score of 3 or less

Limitations
• Relatively small sample size
• Retrospective study with nonblinded researchers
• Internal validity could be improved through further blinding the
physicians assessing imaging.
• External validity is limited as this was a single institution study based
on patients who received MT at high volume university affiliated
comprehensive stroke center on the East Coast of the United States.
Inadequate MRI data for FLAIR analysis as initially planned
SELECT Principles
• Value
• MT estimated base case cost $148,600
• MM estimated base case cost $142,000
• Increased cost of $6,600 represented an incremental costeffectiveness ratio (ICER) of $12,120 per QALY. 6
• Risks include, but are not limited to, hemorrhage, emboli,
access site hematoma, radiation exposure, and infection.
• Health Systems
• MT is efficacious up to 24 hours from last known well, however,
time to treatment significantly impacts outcome.
• Approximately 20% of the US population has access to MT
within within 15 minutes while 31% has access in less than 30minutes.5

P Value T. Test
46%
31%

Additional criteria used to identify patients who were hypothesized to
benefit from thrombectomy:
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Overall, the two cohorts’ demographics were comparable. There was
no significant difference in the outcomes between those patients who
received MM or MT. Predictive model did not reach significance in
identifying patients most likely to benefit from MT. There was a trend
towards no benefit in the hypothesized NPTB who received MT.

Table 2: Comparison of mean time to arrival NIHSS, modified Rankin scale
(mRS), and length of stay for medical management and mechanical
thrombectomy.

Post treatment Hemorrhage

Retrospective study of 1,750 consecutive AIS patients admitted to
a comprehensive stroke center (CSC) between 1/16 and 11/19.
Identified 64 patients who met criteria:
–
NIHSS <6
–
LVO involving either M1 or the internal carotid artery
(ICA)
–
48 underwent a MT
Database captured stroke related demographics, comorbidities,
prehospital course, clinical treatments
Imaging data including perfusion, CTA collateral score, and
presence of FLAIR hyperintense vessels were included for
analysis.

74
73%
50%
21%
23%
31%
23%
21%
19%
15%
0%
6%
6%
15%
8%
10%
2%
2%
15%
25%
35%
8%
48%
31%
63%
42%
6%
10%
4%

Table 1: Demographics comparing medical management vs. mechanical
thrombectomy.

Neurologic improvement or recovery
prior to presentation at CSC
Received TPA

•

Mechanical
Medical Management Thrombectomy
69
63%
69%
38%
6%
13%
25%
13%
6%
0%
6%
13%
0%
0%
0%
0%
0%
0%
13%
25%
38%
0%
63%
19%
31%
38%
0%
6%
0%

There was a trend in improved 90-day mRS for patients with
unchanged or worsened presentations who received a MT over
those who were MM, but it did not reach significance. Additional
studies are needed to identify which subset of LVO patients with
NIHSS<6 are likely to benefit from MT.
Future Steps
Non-blinded retrospective application of criteria has clear limitations, but
it may provide a basis to move forward into a randomized prospective
trial and eventual development of evidence supported therapeutic
guidelines. In the US MT are typically performed by specialist from
neurology, neurosurgery, interventional radiology and diagnostic
radiology. Decisions are often made in collaboration with members of
the stroke team including vascular neurologist and neuroradiologist.
From our study it remained unclear what are common qualitative and
quantitative findings that may lead to a patient with an NIHSS <6 to
receive a MT over MM. Prior to additional retrospective studies it may be
beneficial to conduct a survey to better understand the current clinical
decision making for used which patients with a NIHSS<6 are selected to
undergo mechanical thrombectomy. Accounting for the current process
will aid in eliminating bias in future retrospective trials and allow for
better design of prospective trials.
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